Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy ...

Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a ...

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.

日本福岛第一核电站2号机组核燃料残渣首次被取出 ...

The QIB Mobile App now supports Mobile Wallet transfers to new destinations which are the Philippines and Nepal. These ...

OCR transforms physical documents, such as passports and QIDs, into machine-readable text, speeding up the Know Your Customer ...

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% increase CAPLYTA’s strong prescription uptake continues: Q3 ...